Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS OTCMKTS:ATBPD NASDAQ:PMVP NASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.58+3.9%$1.43$1.05▼$5.17$164.59M0.381.19 million shs507,657 shsATBPDAntibe Therapeutics$0.22$2.64▼$3.50$1.21B0.5729,710 shsN/APMVPPMV Pharmaceuticals$1.34+0.8%$1.04$0.81▼$1.82$69.10M1.49198,733 shs279,702 shsSUPNSupernus Pharmaceuticals$33.52+0.0%$32.36$27.05▼$40.28$1.88B0.7490,215 shs1.20 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+3.95%+2.60%+9.72%+38.60%+17.91%ATBPDAntibe Therapeutics0.00%0.00%0.00%0.00%-0.19%PMVPPMV Pharmaceuticals+0.75%+3.88%+25.23%+31.37%-20.24%SUPNSupernus Pharmaceuticals+0.03%+2.60%+3.23%+8.97%+15.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.0195 of 5 stars3.61.00.00.02.01.70.6ATBPDAntibe TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APMVPPMV Pharmaceuticals3.1551 of 5 stars3.53.00.00.03.32.50.6SUPNSupernus Pharmaceuticals1.6492 of 5 stars1.21.00.04.13.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$8.71451.54% UpsideATBPDAntibe Therapeutics 0.00N/AN/AN/APMVPPMV Pharmaceuticals 3.00Buy$5.50310.45% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.007.40% UpsideCurrent Analyst Ratings BreakdownLatest ACRS, ATBPD, SUPN, and PMVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ACRSAclaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.006/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/23/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/28/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.005/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M9.14N/AN/A$1.44 per share1.10ATBPDAntibe Therapeutics$7.51M0.00N/AN/A$0.10 per share0.00PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/ASUPNSupernus Pharmaceuticals$661.82M2.84$4.17 per share8.03$18.76 per share1.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)ATBPDAntibe Therapeutics-$14.54M-$0.60N/AN/AN/A-273.96%-150.49%-98.51%N/APMVPPMV Pharmaceuticals-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1130.2023.28N/A9.27%12.23%9.17%8/5/2025 (Estimated)Latest ACRS, ATBPD, SUPN, and PMVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39N/AN/AN/AN/AN/A8/6/2025Q2 2025ACRSAclaris Therapeutics-$0.14N/AN/AN/A$1.34 millionN/A8/5/2025Q2 2025SUPNSupernus Pharmaceuticals$0.47N/AN/AN/A$154.06 millionN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/A5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AATBPDAntibe TherapeuticsN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A5.065.06ATBPDAntibe TherapeuticsN/A5.975.42PMVPPMV PharmaceuticalsN/A16.7516.75SUPNSupernus PharmaceuticalsN/A2.442.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ATBPDAntibe TherapeuticsN/APMVPPMV Pharmaceuticals90.20%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%ATBPDAntibe TherapeuticsN/APMVPPMV Pharmaceuticals7.57%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million101.35 millionOptionableATBPDAntibe Therapeutics47387.00 millionN/ANot OptionablePMVPPMV Pharmaceuticals5051.95 million48.02 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million51.06 millionOptionableACRS, ATBPD, SUPN, and PMVP HeadlinesRecent News About These CompaniesTributary Capital Management LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)1 hour ago | marketbeat.comPrincipal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 15 at 3:26 AM | marketbeat.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14 at 4:25 PM | businesswire.comRice Hall James & Associates LLC Sells 12,456 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 14 at 6:35 AM | marketbeat.comStephens Investment Management Group LLC Has $56.94 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 13, 2025 | marketbeat.comWall Street Zen Upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to BuyJuly 12, 2025 | marketbeat.com2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with CautionJuly 10, 2025 | finance.yahoo.comBranded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)July 9, 2025 | msn.comMeritage Portfolio Management Acquires 10,622 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)July 4, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (SUPN) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.com8,151 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Robeco Institutional Asset Management B.V.July 3, 2025 | marketbeat.comSage Sacks Entire Staff After Supernus BuyoutJune 30, 2025 | biospace.comBSupernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJune 27, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five yearsJune 23, 2025 | uk.finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street ZenJune 21, 2025 | marketbeat.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJune 18, 2025 | businesswire.comSupernus Pharma to Buy Sage Therapeutics for Up to $795 MillionJune 16, 2025 | marketwatch.comSupernus enters depression drug market with up to $795 million Sage dealJune 16, 2025 | msn.comSupernus to acquire depression drugmaker SageJune 16, 2025 | msn.comSupernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage TherapeuticsJune 16, 2025 | msn.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.June 16, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRS, ATBPD, SUPN, and PMVP Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.58 +0.06 (+3.95%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.60 +0.02 (+1.58%) As of 09:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Antibe Therapeutics OTCMKTS:ATBPDAntibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.PMV Pharmaceuticals NASDAQ:PMVP$1.34 +0.01 (+0.75%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.35 +0.01 (+0.67%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Supernus Pharmaceuticals NASDAQ:SUPN$33.52 +0.01 (+0.03%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$33.30 -0.22 (-0.66%) As of 09:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
